Adial Pharmaceuticals has recently obtained a new US patent (number 11,905,562) for their leading investigational drug, AD04, which targets the serotonin transporter gene to potentially treat opioid use disorder. This patent adds to Adial’s intellectual property portfolio and expands the scope of AD04’s unique ability to target the serotonin transporter gene for addressing opioid use disorder.
CEO Cary Claiborne of Adial Pharmaceuticals expressed pride in this achievement, emphasizing the importance of this patent in strengthening their IP portfolio and highlighting AD04’s potential to treat not only alcohol use disorder but also other drug dependencies, including opioid use disorder. The company is focused on moving AD04 towards commercialization for alcohol use disorder treatment while also exploring its potential for treating opioid use disorder and other conditions in the future.
Earlier this month, Adial Pharmaceuticals was also granted another US patent that extends the coverage of their proprietary genetic diagnostic tool for identifying patients with specific genotypes suitable for genetically targeted treatment of alcohol use disorder and drug dependencies like opioid use disorder. This patent further bolsters Adial’s intellectual property estate and underscores their commitment to offering personalized treatment solutions for individuals struggling with addiction.
ADIL Stock Shows Promising Signs of Price Momentum Despite Trading Near Bottom – February 28, 2024
On February 28, 2024, ADIL stock showed some promising signs of price momentum despite trading near the bottom of its 52-week range and below its 200-day simple moving average. The stock closed at $0.87, which was an increase of $0.04 or 4.83% since the market last closed. After-hours trading saw a slight dip in the stock price, with ADIL dropping $0.03. ADIL’s recent increase may be a sign of potential growth, but investors should also take into account the stock’s overall trends and performance over time. It’s recommended to conduct thorough research and consult with a financial advisor before making any investment decisions.
ADIL Stock Performance Analysis: Positive Trends in Net Income and EPS – February 28, 2024
On February 28, 2024, ADIL stock showed some interesting performances based on the available data. Despite the lack of information on total revenue, the net income figures provide some insight into the company’s financial health.
According to CNN Money, ADIL reported a net income of -$12.73 million over the past year, which represents a 34.45% increase compared to the previous year. In the most recent quarter, the company reported a net income of -$1.35 million, showing a 10.74% increase compared to the previous quarter. These figures suggest that ADIL has been able to improve its financial performance over time, despite still operating at a loss.
Furthermore, the earnings per share (EPS) figures also show positive trends for ADIL. The EPS over the past year was reported at -$12.71, indicating a 51.34% increase compared to the previous year. In the most recent quarter, the EPS was reported at -$1.14, showing a 17.82% increase compared to the previous quarter. This indicates that ADIL has been able to increase its earnings per share over time, which could be seen as a positive sign for investors.
Overall, while the lack of total revenue data makes it difficult to provide a comprehensive analysis of ADIL’s stock performance on February 28, 2024, the net income and EPS figures suggest that the company has been able to make some improvements in its financial performance. Investors may want to keep an eye on ADIL stock to see if these positive trends continue in the future.
